Figure 5.

Histological assessment of the efficacy of the ABP dendrimer when administered topically to IMQ-induced psoriatic mice. Representative pictures of the skin of the back of mice stained with hematoxylin/eosin at day 7 from psoriatic control mouse (representative of n = 5 mice) (A), and from mice treated daily with 5 mg/kg (representative of n = 5 mice) (B) and 50 mg/kg (representative of n = 6 mice) (C) of the ABP dendrimer; black scale bars represent 50 µm. Single-headed arrows point the granular layer (absent in (A)), double-headed arrows show acanthosis, single arrow heads show parakeratosis (lowered in (B) and (C)), diamonds show hyperkeratosis (lowered in (B) and (C)), double arrow heads show infiltration of immune cells. (D) Scoring of the histological assessment of the skin of the back for each group of mice; *** p < 0.001 versus untreated mice (concentration of ABP = 0 mg/kg) using the Kruskal–Wallis’ test followed by the post hoc Dunn’s test. (E) Measurement of the thickness of the skin of the back for each group of mice at day 6; ** p < 0.01 versus untreated mice (concentration of ABP = 0 mg/kg) using the Kruskal–Wallis’ test followed by the post hoc Dunn’s test.